AstraZeneca, Gatehouse Bio extend partnership to develop RNA therapeutics for heart failure
The collaboration will combine AstraZeneca’s expertise in RNA therapeutics with Gatehouse Bio’s capabilities in small RNA compounds to…
Moderna to supply additional doses of bivalent Covid-19 booster vaccine to US
01 Aug 22Under the new agreement with the US government, the biotechnology company will receive up to $1.74bn for 66…
Bavarian Nordic to supply additional monkeypox shots to US, Europe
18 Jul 22Jynneos is a liquid-frozen non-replicating smallpox vaccine that has been approved by the US Food and Drug Administration…
GenScript, ACT Therapeutics partner to develop new CAR-T Cell therapies
13 Jul 22GenScript ProBio will support ACT therapeutics’ CAR-T Platform (ACT platform), an immune cell-based cell and gene therapy technology…
Roche licenses Ionis’ investigational therapy for rare kidney disease
12 Jul 22Ionis will receive $55m from Roche, in exchange for licensing IONIS-FB-LRx and achieving a development milestone in the…
Akebia terminates license deal with Otsuka to retain vadadustat rights
04 Jul 22The company is entitled to receive a settlement fee of $55m and will assume responsibility for the marketing…
ViiV Healthcare teams up with MPP to license patents related to HIV drug cabotegravir
30 May 22ViiV Healthcare and MPP are actively negotiating on terms of a voluntary licensing agreement, which would help widen…
Biogen partners with MedRhythms to develop digital therapeutic for multiple sclerosis
06 May 22MR-004 is an investigational prescription digital therapeutic that leverages a combination of sensors, software, and music based on…
Exscientia, Oxford TDI partner for Xcellomics drug discovery programme
11 Mar 22Xcellomics programme was created by the two Oxford-based institutions to advance the early-stage drug discovery research by academic…
AstraZeneca, Neurimmune to jointly develop cardiomyopathy drug NI006
02 Mar 22Alexion will obtain an exclusive licence to develop, manufacture and market NI006, and will pay $30m upfront, and…